IP Library Granted Patent US 7,964,565
Granted Patent B2
US 7,964,565 · App. 11/576,591 · Granted Jun 21, 2011

Method of inhibiting inflammation in a mammal by administering Bcl protein

Assignee: University of Washington Center for Commercialization, a Public Institution of Higher Education
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,964,565
App. No.
11/576,591
Granted
Jun 21, 2011
Kind
B2
Abstract

In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal.

Claims (10)

1. A method for inhibiting inflammation in a mammal suffering from inflammation, the method comprising administering to the mammal an isolated Bcl protein comprising an amino acid sequence at least 90% similar to the amino acid sequence set forth in SEQ ID NO:4 in an amount sufficient to inhibit inflammation in the mammal.

2. The method of claim 1 , wherein the mammal is suffering from ischemia.

3. The method of claim 1 , wherein the mammal is a human being.

4. The method of claim 1 , wherein the Bcl protein is administered intravenously.

5. The method of claim 1 , wherein the Bcl protein is administered subcutaneously.

6. The method of claim 1 , wherein the Bcl protein is administered intraperitoneally.

7. The method of claim 1 , wherein the Bcl protein is administered transdermally.

8. The method of claim 1 , wherein the Bcl protein is administered to the mammal in an amount from 0.5 μg/kg/day to 50 μg/kg/day for a period of time sufficient to inhibit inflammation in the mammal.

9. The method of claim 8 , wherein the Bcl protein is administered to the mammal for a period of from 1 day to 20 days.

10. The method of claim 8 , wherein the Bcl protein is administered to the mammal at least once per day.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jul 6, 2012
From: UNIVERSITY OF WASHINGTON / CENTER OF COMMERCIALIZATION
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028503/0430 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Sep 16, 2008
From: UNIVERSITY OF WASHINGTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021533/0177 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2008
From: HARLAN, JOHN M.; WINN, ROBERT K.; IWATA, AKIKO; TUPPER, JOAN; LI, JOHN
To: UNIVERSITY OF WASHINGTON
Reel/Frame 021162/0189 →
Continuity (3)
Provisional Application 60714511 · Oct 4, 2004
Provisional Application 60709053 · Aug 16, 2005
Related Publication 20110082072A1 · Apr 7, 2011